Close Close
Sign In
Newsletters
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
Podcast Center Video Center Webcasts Resource Center Events
About ThinkAdvisor Contact Us Advertise With Us Asset & Logo Licensing Sitemap Terms of Service Privacy Policy Copyright © 2024 ALM Global, LLC. All Rights Reserved.
ThinkAdvisor

Life Health > Health Insurance > Life Insurance Strategies

Blues: New Generic Drugs Could Lower Costs

By Kimberly Parent

X
Your article was successfully shared with the contacts you provided.

Expiring patents on 2 popular prescription medications could save consumers, employers and health insurers billions of dollars per year.

The Blue Cross and Blue Shield Association, Chicago, and some of the association’s member companies are making those predictions in response to major developments in the world of generic drugs.

A generic version of Zocor, or simvastatin, a cholesterol-lowering drug has just come out, and the patent on Zoloft, a brand-name version sertraline, will expire next week.

Availability of generic versions of those 2 drugs alone will lead to dramatic changes in the prescription drug market, the Blues say.

“A switch to generic versions of Zocor and Zoloft represents a watershed event,” Dr. Allan Korn, the Blue Cross and Blue Shield Association chief medical officer, says in a statement.

Zocor, the second most widely prescribed statin, lowers the amount of fat, or lipids, in the blood. Zocor accounted for $4.6 billion in U.S. sales in 2004, according to IMS Health, Fairfield, Conn.

Moreover, Reuters carried an article earlier this week quoting David Fedson, a researcher who believes that statins could help reduce the severity of the bird flu in the event of a pandemic.

Zoloft, a selective serotonin reuptake inhibitor, generated $3.1 billion in U.S. sales in 2004, IMS says.

Competition from generic versions of Zocor and Zoloft could lead to 30% to 80% reductions in the cost of those drugs and the new generic alternatives, IMS says.

IMS notes that branded drugs that generate a total of $18 billion to $20 billion in U.S. sales will lose patent protection this year.

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.